Nicorette® is expanding evidence-based support for adults who want to quit smoking, vaping, or nicotine altogether in Europe. In the U.K., Nicorette® QuickMist became the first medicine licensed for vaping cessation in 2023, and in 2025 that indication expanded across the full Nicorette® portfolio. The brand is also supporting public health dialogue on youth nicotine addiction and cessation policy.
Smokingremainsa leading preventable cause of death in the U.K., while vaping among young people continues to raise public health concerns. Nicorette® is responding by expanding evidence-based support for adults who want to quit smoking, vaping, or nicotine altogether, while also helping advance dialogue on youth nicotine addiction and modern cessation policy. This work isinformed by Kenvue’s focus on enablinghealthieroutcomes for people and communities.
What is Nicorette® doing to support smoking and vaping cessation in Europe?
In the U.K., Nicorette® QuickMist became the first medicine licensed for vaping cessation in 2023, marking an important milestone in nicotine dependence treatment. In 2025, that vaping cessation indication expanded across the full Nicorette® portfolio, helping more adults access trusted, evidence-based support to quit nicotine for good.
Nicorette® is also engaging in public health dialogue across Europe. In 2025, the brand joined discussions with the World Health Organization, the European Network for Smoking and TobaccoPrevention, and European Union policymakers on youth nicotine addiction and the need for public health frameworks that reflect today’s changing nicotine landscape. Nicorette® has also supported evidence-based cessation dialogue through the reportEndgame: Managing the Disposable Vapes Ban and the Journey to a Smokefree Future.
What’s next for Nicorette® in Europe?
Whether adults are trying to quit cigarettes, vaping, or nicotine altogether, Nicorette® aims to provide trusted support that can help them make lasting change. Guided by Kenvue’s Healthy Lives Mission, the brand continues to focus on expanding access to cessation support and contributing to public health efforts across Europe.